UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
36.09 USD
+0.09 (+0.25%)
At close:
36.1 USD
+0.01 (+0.03%)
After Hours:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- UTI had positive earnings in the past year.
- UTI had a positive operating cash flow in the past year.
- Each year in the past 5 years UTI has been profitable.
- In the past 5 years UTI always reported a positive cash flow from operatings.
1.2 Ratios
- UTI has a Return On Assets of 6.44%. This is in the better half of the industry: UTI outperforms 73.97% of its industry peers.
- UTI's Return On Equity of 15.98% is fine compared to the rest of the industry. UTI outperforms 75.34% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 8.69%, UTI is in the better half of the industry, outperforming 75.34% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for UTI is below the industry average of 10.88%.
- The last Return On Invested Capital (8.69%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- UTI has a better Profit Margin (6.28%) than 65.75% of its industry peers.
- In the last couple of years the Profit Margin of UTI has grown nicely.
- UTI's Operating Margin of 8.38% is fine compared to the rest of the industry. UTI outperforms 65.75% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- Looking at the Gross Margin, with a value of 49.62%, UTI is in line with its industry, outperforming 54.79% of the companies in the same industry.
- UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- UTI has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for UTI has been increased compared to 1 year ago.
- Compared to 5 years ago, UTI has more shares outstanding
- The debt/assets ratio for UTI has been reduced compared to a year ago.
2.2 Solvency
- UTI has an Altman-Z score of 3.93. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- UTI has a Altman-Z score of 3.93. This is in the better half of the industry: UTI outperforms 79.45% of its industry peers.
- The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of UTI (6.28) is better than 71.23% of its industry peers.
- A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
- UTI has a Debt to Equity ratio (0.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 3.93 |
ROIC/WACC1
WACC8.68%
2.3 Liquidity
- UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI has a Current ratio (1.14) which is comparable to the rest of the industry.
- UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI has a Quick ratio (1.14) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- Measured over the past years, UTI shows a very strong growth in Earnings Per Share. The EPS has been growing by 65.96% on average per year.
- The Revenue has grown by 12.59% in the past year. This is quite good.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- UTI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.89% yearly.
- UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.84% yearly.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 37.21, the valuation of UTI can be described as expensive.
- UTI's Price/Earnings ratio is in line with the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 25.96, UTI is valued a bit more expensive.
- The Price/Forward Earnings ratio is 39.30, which means the current valuation is very expensive for UTI.
- The rest of the industry has a similar Price/Forward Earnings ratio as UTI.
- UTI is valuated expensively when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.21 | ||
| Fwd PE | 39.3 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
- UTI's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 123.04 | ||
| EV/EBITDA | 17.53 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
36.09
+0.09 (+0.25%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-05 2026-05-05
Inst Owners97.17%
Inst Owner Change7.31%
Ins Owners2.7%
Ins Owner Change3.59%
Market Cap1.99B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (6.46%)
Short Float %6.37%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0.64%
PT rev (3m)0.64%
EPS NQ rev (1m)-107.15%
EPS NQ rev (3m)-103.82%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.21 | ||
| Fwd PE | 39.3 | ||
| P/S | 2.32 | ||
| P/FCF | 123.04 | ||
| P/OCF | 25.64 | ||
| P/B | 5.91 | ||
| P/tB | 6.93 | ||
| EV/EBITDA | 17.53 |
EPS(TTM)0.97
EY2.69%
EPS(NY)0.92
Fwd EY2.54%
FCF(TTM)0.29
FCFY0.81%
OCF(TTM)1.41
OCFY3.9%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.56
Graham Number11.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 3.93 |
F-Score7
WACC8.68%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.